Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Mercian Corporation and Eisai Co., Ltd.

Toshiaki Wakabayashi

Yasuhiro Funahashi

Taro Semba

Naoko Hata

Norihiro Ueda

Akihiko Tsuruoka

Keiko Takahashi

Yuji Yamamoto

Tadashi Okabe

Toru Haneda

Kazumasa Nara

Junichi Kamata

Takashi Owa

Shinichi Hamaoka

Yoichi Ozawa

Noako Tsukahara

Yoshio Watanabe

Kazuyuki Dobashi

Tomohiro Sameshima

Masanori Fujita

Naoko Tsukahara

Naoto Ono

Taro Senba

Nobuaki Naruse

Rena Kawase

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, &#x2014;CH&#x2550;CH&#x2014; or &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mmeans an integer of 1 or 2); Rmeans hydrogen atom or a C1-C6 alkyl group; Z means a single bond or &#x2014;CO&#x2014;NH&#x2014;; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Integrin expression inhibitor

The present invention provides a system for testing the influence of a drug on integrin expression, which comprises measuring an integrin expression level in platelets of an individual to which the drug is administered and, based on the measured expression amount, determining what effect the drug has on integrin expression in cells other than platelets.

Method for testing effect of angiogenesis inhibitor via integrin expression inhibition

Sulfonamide-containing heterocyclic compounds

Sulfonamide-containing indole compounds

Physiologically active substances

Growing community of inventors

Ibaraki, Japan

Toshiaki Wakabayashi